This content is machine translated IMPAKT 2017 Breast Cancer Conference, Brussels CDK4/6 inhibitor – therapeutic option in triple-negative breast carcinoma? A new study provides insights into the mechanisms of resistance in triple-negative breast carcinoma (TNBC) and therapy with CDK4/6 inhibitors. Previously known from the treatment regimen of advanced hormone receptor…
